Related Experiment Videos
Cyclic bisphosphonate therapy in osteogenesis imperfecta type V.
F Fleming1, H J Woodhead, J N Briody
1Department of Clinical Genetics, The Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Journal of Paediatrics and Child Health
|March 26, 2005
Summary
This study details Osteogenesis Imperfecta Type V management in a child, showing pamidronate treatment improved bone density and reduced fractures. The findings highlight effective therapeutic options for this rare bone disorder.
Area of Science:
- Pediatric Endocrinology
- Skeletal Dysplasias
- Bone Metabolism
Background:
- Osteogenesis Imperfecta (OI) is a group of genetic disorders characterized by fragile bones.
- Type V OI, recently delineated, presents unique clinical and radiographic features.
- Early diagnosis and management are crucial for improving patient outcomes.
Observation:
- A 9-year-old female with a history of multiple fractures since age 3 and bilateral elbow dislocations from infancy.
- Clinical presentation included significant bone fragility and joint abnormalities.
- Radiographic evaluation confirmed features consistent with Osteogenesis Imperfecta Type V.
Findings:
- The patient was treated with a low-dose, frequent regimen of cyclic intravenous pamidronate.
- Treatment resulted in progressive improvement in bone mineral density.
- A significant reduction in fracture frequency and remission of osteoporosis symptoms were observed.
Implications:
- Intravenous pamidronate is an effective treatment for Osteogenesis Imperfecta Type V in pediatric patients.
- This management strategy can lead to improved bone health and reduced morbidity.
- Further research into long-term outcomes and optimal dosing for OI Type V is warranted.